Cited 99 times in
Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2018-05-10T06:40:43Z | - |
dc.date.available | 2018-05-10T06:40:43Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/158422 | - |
dc.description.abstract | BACKGROUND: Hepatitis B virus (HBV) reactivation is increasing, as rituximab has become widely used for B-cell lymphoma. Thus, prevention and management of HBV reactivation are important in HBV-endemic areas. METHODS: Hepatitis B virus (HBV) reactivation in HBV surface antigen (HBsAg)-positive patients and HBsAg-negative/HBV core antibody (HBcAb)-positive patients who received rituximab-containing chemotherapy was investigated by the Asia Lymphoma Study Group via retrospective (n=340), and the results were compared to cross-sectional analysis with patients who were prospectively monitored in a single institute (n=127). The goal of the study was to define the frequency of HBV reactivation and the efficacy of antiviral prophylaxis. RESULTS: HBV reactivation was found in 27.8% of HBsAg-positive patients (45/162) in the retrospective analysis, being significantly less frequent in patients receiving antiviral prophylaxis than those not (22.9%, 32/140 versus 59.1%, 13/22; p<0.001). Lamivudine was most commonly used (96/162, 59.3%), but more than 20% of HBsAg-positive patients showed breakthrough HBV reactivation. In the cross-sectional analysis, a reduced rate of HBV reactivation occurred for entecavir as compared with lamivudine prophylaxis (6.3% versus 39.3%; p<0.05). HBV DNA monitoring of HBsAg-negative/HBcAb-positive patients in the cross-sectional analysis showed HBV reactivation in only 2.4% of cases. CONCLUSIONS: This is the largest study of HBV reactivation in patients receiving rituximab-containing chemotherapy to date, and we defined the probability of HBV reactivation in an HBV-endemic region. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier Science Ltd | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Antibodies, Monoclonal, Murine-Derived/adverse effects | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antiviral Agents/therapeutic use | - |
dc.subject.MESH | Asia/epidemiology | - |
dc.subject.MESH | Biomarkers/blood | - |
dc.subject.MESH | Cross-Sectional Studies | - |
dc.subject.MESH | DNA, Viral/blood | - |
dc.subject.MESH | Endemic Diseases | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hepatitis B/blood | - |
dc.subject.MESH | Hepatitis B/diagnosis | - |
dc.subject.MESH | Hepatitis B/epidemiology | - |
dc.subject.MESH | Hepatitis B/prevention & control | - |
dc.subject.MESH | Hepatitis B Surface Antigens/blood | - |
dc.subject.MESH | Hepatitis B virus/drug effects | - |
dc.subject.MESH | Hepatitis B virus/genetics | - |
dc.subject.MESH | Hepatitis B virus/immunology | - |
dc.subject.MESH | Hepatitis B virus/physiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Incidence | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Lymphoma, B-Cell/drug therapy | - |
dc.subject.MESH | Lymphoma, B-Cell/epidemiology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Rituximab | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Viral Load | - |
dc.subject.MESH | Virus Activation/drug effects | - |
dc.title | Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Seok Jin Kim | - |
dc.contributor.googleauthor | Chiun Hsu | - |
dc.contributor.googleauthor | Yu-Qin Song | - |
dc.contributor.googleauthor | Kevin Tay | - |
dc.contributor.googleauthor | Xiao-Nan Hong | - |
dc.contributor.googleauthor | Junning Cao | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Hyeon Seok Eom | - |
dc.contributor.googleauthor | Joon Hyeok Lee | - |
dc.contributor.googleauthor | Jun Zhu | - |
dc.contributor.googleauthor | Kian-Meng Chang | - |
dc.contributor.googleauthor | Arry Harryanto Reksodiputro | - |
dc.contributor.googleauthor | Daryl Tan | - |
dc.contributor.googleauthor | Yeow Tee Goh | - |
dc.contributor.googleauthor | Jejung Lee | - |
dc.contributor.googleauthor | Tanin Intragumtornchai | - |
dc.contributor.googleauthor | Wee-Joo Chng | - |
dc.contributor.googleauthor | Ann-Lii Cheng | - |
dc.contributor.googleauthor | Soon Thye Lim | - |
dc.contributor.googleauthor | Cheolwon Suh | - |
dc.contributor.googleauthor | Yok-Lam Kwong | - |
dc.contributor.googleauthor | Won Seog Kim | - |
dc.identifier.doi | 10.1016/j.ejca.2013.07.006 | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J00809 | - |
dc.identifier.eissn | 1879-0852 | - |
dc.identifier.pmid | 23910494 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0959804913005558 | - |
dc.subject.keyword | B-cell | - |
dc.subject.keyword | Hepatitis B virus | - |
dc.subject.keyword | Lymphoma | - |
dc.subject.keyword | Rituximab | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | Kim, Jin Seok | - |
dc.citation.volume | 49 | - |
dc.citation.number | 16 | - |
dc.citation.startPage | 3486 | - |
dc.citation.endPage | 3496 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF CANCER, Vol.49(16) : 3486-3496, 2013 | - |
dc.identifier.rimsid | 42423 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.